Prescriptions for GLP-1s approved for weight loss fell about 84% in four states that ended Medicaid coverage of the drugs, compared with states that maintained coverage, according to a study published Nov. 16 in JAMA.
Here are six things to know:
- California, New Hampshire, Pennsylvania and South Carolina withdrew Medicaid coverage of GLP-1s approved for weight loss Jan. 1, citing high costs. University of Pittsburgh researchers used Medicaid State Drug Utilization Data, which includes fee-for-service and managed care prescriptions, to compare the four states with 10 states that maintained coverage.
- Between the last quarter of 2025 and the first quarter of 2026, prescriptions for GLP-1s approved for weight loss in the states that ended coverage fell from 2,914 to 421 per 100,000 Medicaid beneficiaries, according to the university.
- Pennsylvania had the steepest decline, at 95.5%, followed by New Hampshire at 88%, California at 75.2% and South Carolina at 60.8%.
- The authors estimated that 175,500 to 526,600 fewer Medicaid beneficiaries filled these prescriptions after coverage ended. They found no statistically significant increase in the use of GLP-1s approved for diabetes in the states that withdrew coverage.
- Seventeen state Medicaid programs have added optional coverage of GLP-1s approved for weight loss since 2022, and most use prior authorization to control utilization, the authors noted. Medicaid is not required to cover weight loss drugs, unlike nearly all other outpatient drugs.